Clinical Trial Update: Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sipuleucel-T with or without radium-223 in men with asymptomatic or minimally symptomatic bone-metastatic castration-resistant prosta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Radium-223 (radium-223 dichloride)
• sipuleucel-T (sipuleucel-T)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-07-08